Last reviewed · How we verify
Prevention of atherothrombotic events in symptomatic peripheral artery disease
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of atherothrombotic events in symptomatic peripheral artery disease patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of atherothrombotic events in symptomatic peripheral artery disease treatment landscape brief
- Prevention of atherothrombotic events in symptomatic peripheral artery disease treatment updates RSS
Frequently asked questions about Prevention of atherothrombotic events in symptomatic peripheral artery disease
What drugs treat Prevention of atherothrombotic events in symptomatic peripheral artery disease?
Tracked treatments include Xarelto.
What is the treatment for Prevention of atherothrombotic events in symptomatic peripheral artery disease?
Standard treatment for Prevention of atherothrombotic events in symptomatic peripheral artery disease includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of atherothrombotic events in symptomatic peripheral artery disease patent cliff · Prevention of atherothrombotic events in symptomatic peripheral artery disease CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing